CRESS | $234,000 | (Feb 21, 2025)
Safe Intelligence | $5,253,443 | (Feb 21, 2025)
Reverb Therapeutics | $21,000,000 | (Feb 21, 2025)
MimiVax, LLC
United States
- Buffalo, NY
- 10/12/2021
- Unknown
- $5,000,000
Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates
MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer.
SurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2 clinical trial in adults with newly diagnosed glioblastoma. Additional indications are being evaluated through Phase 1 clinical trials in multiple myeloma combination with REVLIMID® (lenalidomide) as well as Phase 1 in Neuro-Endocrine Tumors (NET)
- Industry Pharmaceutical Manufacturing
- Website https://www.mimivax.com/
- LinkedIn https://www.linkedin.com/company/mimivax-llc/
Related People
Michael CiesielskiFounder
United States -
Buffalo-Niagara Falls Area
At MimiVax, our mission is to disrupt cancer. To increase survival and send hope through the development of highly innovative immunotherapies aimed at improving patient's lives.
QuSecure | $28,000,000 | (Feb 21, 2025)
AheadComputing | $21,500,000 | (Feb 21, 2025)
Together AI | $30,000,000 | (Feb 21, 2025)
Kodesage | $2,300,000 | (Feb 21, 2025)
OpenEvidence | Undisclosed Amount | (Feb 21, 2025)
Oso Semiconductor | $5,200,000 | (Feb 21, 2025)
EnPlusOne Biosciences | $10,000,000 | (Feb 21, 2025)
Pinkfish | $7,600,000 | (Feb 21, 2025)
Esperto Medical | Undisclosed Amount | (Feb 21, 2025)